MF59 and AS03 are preparations of squalene (“SKWAH-leen”) that intensify variants of this product respectively developed by Novartis and GSK. COVID-19 removed the need for this product to address both the Yamagata (10[1])and Victoria lineages. Deployment (10[1])of an early iteration (10[1])of this product coincided with a fourfold increase in (10[1])Guillain–Barré (“ghee-LAN bah-RAY”) syndrome. (10[3])Individuals with albumin allergies (10[1])can use this product even though it is primarily (-5[1])produced (-5[1])in the allantoic cavity of fertilized chicken eggs. (10[3])This product (10[1])does not need a cold chain because it is the most prevalent product in the US to use thimerosal. (10[1]-5[2])This (-5[1])product (10[1])is either trivalent or tetravalent to account for antigenic shift. (-5[1])For 10 points, name this product made available every winter (10[3])to address endemic strains (10[1])of H3N2 and H1N1. ■END■ (10[6])